Related Experiment Video

Updated: May 28, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Programmable miRNA-guided RNA-toxin switch for selective elimination of cancer cells

Xinghuan Ma1, Yufeng Zhang2, Sujia Liu2

  • 1Department of Hepatopancreatobiliary Surgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning 110042, China; MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian 116024, China.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|May 27, 2026
PubMed

Insights

Researchers developed miRNA-guided RNA-Toxin Constructs (miR-RTCs) for cancer therapy. These constructs target tumors specifically by using microRNA (miRNA) to control toxin release, reducing side effects and improving treatment efficacy.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Oncology

Background:

  • Chemo- and targeted therapies cause severe side effects due to systemic damage to healthy cells.
  • There is a need for cancer therapeutics with improved tumor selectivity and reduced off-target effects.

Purpose of the Study:

  • To develop a novel RNA therapeutic platform, miRNA-guided RNA-Toxin Constructs (miR-RTCs), for precise cancer cell elimination.
  • To leverage microRNA (miRNA) dysregulation in tumor cells for targeted toxin expression.

Main Methods:

  • Design of miR-RTCs as miRNA-responsive molecular switches.
  • Systemic delivery of miR-RTCs in hepatocellular carcinoma mouse models.
  • Assessment of tumor selectivity, protein expression, and anti-tumor efficacy in vivo.

Main Results:

  • miR-RTCs demonstrated superior tumor selectivity by conditionally expressing toxic proteins in response to tumor-specific miRNA profiles.
  • Systemic delivery resulted in restricted protein expression to tumor regions.
  • Significant tumor regression was observed with minimal off-target effects in hepatocellular carcinoma models.

Conclusions:

  • miR-RTCs represent a programmable RNA therapeutic platform overcoming selectivity limitations of traditional chemotherapy.
  • This approach offers potent anti-tumor efficacy with enhanced safety profiles.
  • Potential for combination with immunotherapy for further therapeutic enhancement.
Keywords:
RNA circuitsmRNA drugsmiRNAselective translationsequence optimizationtoxic proteinstumor targeting

More Related Videos

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...